← All Kymera Therapeutics, INC filings

Kymera Therapeutics, INC DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

NASDAQ
KYMR
Kymera Therapeutics, INC
DEFA14A: Kymera Therapeutics Sets Date for 2025 Annual Shareholder Meeting
Kymera Therapeutics announces its 2025 Annual Meeting of Shareholders to be held virtually on June 25, 2025, with voting open until June 24, 2025.
NASDAQ
KYMR
Kymera Therapeutics, INC
DEF 14A: Kymera Therapeutics Sets Date for 2025 Annual Shareholder Meeting, Outlines Key Proposals
Kymera Therapeutics announces its 2025 Annual Meeting of Shareholders to be held virtually on June 25, 2025, featuring proposals for director elections, executive compensation approval, and auditor ratification.
NASDAQ
KYMR
Kymera Therapeutics, INC
DEFA14A: Kymera Therapeutics, Inc. Files Definitive Proxy Statement
Kymera Therapeutics, Inc. has filed a definitive proxy statement with the Securities and Exchange Commission.
NASDAQ
KYMR
Kymera Therapeutics, INC
DEF 14A: Kymera Therapeutics Sets Date for 2024 Annual Shareholder Meeting, Outlines Key Proposals
Kymera Therapeutics announces its 2024 Annual Meeting of Shareholders to be held virtually on June 18, 2024, featuring proposals including director elections, executive compensation, and an amendment to the stock option plan.